Skip to main content

Table 3 Baseline characteristics of participants

From: Xuan Bai Cheng Qi formula as an adjuvant treatment of acute exacerbation of chronic obstructive pulmonary disease of the syndrome type phlegm-heat obstructing the lungs: a multicenter, randomized, double-blind, placebo-controlled clinical trial

 

XBCQ (n = 122)

Control (n = 122)

Age (SD), y

70.1 ± 9.8

70.7 ± 9.8

Body mass index (SD), kg/m2

23.36 ± 3.44

22.76 ± 3.11

Gender (male/female)

  

 Male (n) %

88 (72.1%)

82 (67.2%)

 Female (n) %

34 (27.9%)

40 (32.8%)

Body temperature (°C)

36.68 ± 0.56

36.66 ± 0.58

Exacerbation

  

 Frequency (times)

2.8 ± 1.28

2.6 ± 1.24

 Currently exacerbation

3.5 ± 1.36

3.5 ± 1.29

Smoking status

  

 Currently smoking, n (%)

22 (18.03%)

16 (13.11%)

 Never smoked, n (%)

54 (44.26%)

52 (42.62%)

 Ever smoked, n (%)

46 (37.70%)

54 (44.26%)

 No. of packs/year

299.8 ± 170.0

337.9 ± 192.6

FEV1/FVC

55.02 ± 10.477

56.91 ± 9.592

GOLD classification

  

 GOLD stage I, n (%)

10 (8.20%)

9 (7.38%)

 GOLD stage II, n (%)

56 (45.90%)

58 (47.54%)

 GOLD stage III, n (%)

47 (38.52%)

45 (36.89%)

 GOLD stage IV, n (%)

9 (7.38%)

10 (8.20%)

  1. Abbreviations: COPD chronic obstructive pulmonary disease, FEV 1 forced expiratory volume in one second, FVC forced vital capacity, GOLD Global Initiative for Chronic Obstructive Lung Disease, SD standard deviation, XBCQ Xuan Bai Cheng Qi.
Back to article page

BMC Complementary Medicine and Therapies

ISSN: 2662-7671

Contact us